The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-08), Vireo Growth's 5-Day RSI is 44.41.
The industry rank for Vireo Growth's 5-Day RSI or its related term are showing as below:
VREOF's 5-Day RSI is ranked worse than 52.44% of 1043
companies
in the Drug Manufacturers industry
Industry Median: 50.77
vs VREOF: 44.41
Vireo Growth (OTCPK:VREOF) 5-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Vireo Growth 5-Day RSI Related Terms
VREOF vs ZTS, UTHR: 5-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vireo Growth 5-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's 5-Day RSI distribution charts can be found below:
* The bar in red indicates where Vireo Growth's 5-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vireo Growth (VREOF) has a 5-Day RSI of 44.41 as of Jul. 08, 2026. According to the industry distribution chart, Vireo Growth ranks #547 out of 1043 companies in the Drug Manufacturers industry, placing it in the top 52.4%.
Is Vireo Growth's 5-Day RSI too high?
Vireo Growth's current 5-Day RSI is 44.41. The Drug Manufacturers industry median 5-Day RSI is 50.77. Vireo Growth's value of 44.41 is 12.5% below this industry median. Based on the distribution chart, Vireo Growth ranks #547 out of 1043 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vireo Growth has a GF Score™ of 46/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's 5-Day RSI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vireo Growth ranks #547 out of 1043 companies for 5-Day RSI. This places Vireo Growth in the lower half of its industry. The industry median 5-Day RSI is 50.77. Vireo Growth's value of 44.41 is 12.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Day RSI for a Drug Manufacturers company?
The median 5-Day RSI among Drug Manufacturers companies is 50.77, based on 1,043 companies in the industry. Companies in the top quartile (top 25%) have a 5-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 5-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vireo Growth's current 5-Day RSI of 44.41 is 12.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Day RSI mean?
A high 5-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 5-Day RSI is 50.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vireo Growth's current 5-Day RSI is 44.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (VREOF) is currently considered Fairly Valued. The stock's GF Value™ is $9.69, compared to a current price of $9.98 — trading 3% above its estimated fair value. The current 5-Day RSI is 44.41 and 12.5% below the Drug Manufacturers industry median of 50.77. Vireo Growth's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Day RSI calculated?
5-Day RSI is calculated from a company's financial statements. For Vireo Growth (VREOF), the current 5-Day RSI is 44.41 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vireo Growth (VREOF) Overvalued in 2026?
Based on GuruFocus' analysis, Vireo Growth stock appears to be overvalued.
The current stock price of $9.98 is trading 3% above its estimated GF Value™ of $9.69.
GuruFocus considers Vireo Growth to be Fairly Valued.
Key valuation signals for VREOF:
5-Day RSI: 44.41
GF Value™: $9.69 vs. price of $9.98 (3% above fair value)
Industry Position: 12.5% below the Drug Manufacturers median (#547 of 1043)
No single metric tells the full story. See the VREOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
46GF Score
Get the complete analysis for VREOF
5-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VREOF has been successfully added to your 